中国肺癌杂志最新文献

{"title":"[Advances in the Application of Adjuvant Chemotherapy and Targeted Therapy \u2029in Postoperative Patients with Stage I Lung Adenocarcinoma].","authors":"Ke Zhao, Chao Guo, Yeye Chen, Shanqing Li","doi":"10.3779/j.issn.1009-3419.2024.101.26","DOIUrl":"10.3779/j.issn.1009-3419.2024.101.26","url":null,"abstract":"<p><p>Lung cancer is one of the main causes of cancer burden and death in China, with nearly 800,000 newly diagnosed lung cancer patients each year, nearly half of whom are lung adenocarcinoma (LUAD) patients. According to current clinical guidelines, surgery is the main treatment for stage I LUAD patients, but the 5-year overall survival rate of stage I LUAD patients alone is still unsatisfactory, about 73%-90%, indicating that a considerable number of patients require other means to improve survival benefits. Chemotherapy and targeted therapy have achieved great success in the treatment of locally advanced and metastatic LUAD patients, but there is still controversy over whether they can benefit stage I LUAD postoperative patients. Under the circumstances, many researchers have paid attention to this issue and made beneficial explorations. This review provides a brief review of the factors that affect the acceptance of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, as well as the relevant clinical research on the application of adjuvant chemotherapy and targeted therapy in stage I LUAD postoperative patients, in order to gain a broader understanding of the latest developments in this field and find new breakthroughs to promote sustained research in this field.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"777-784"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Progress in the Study of Mechanisms Clinically Relevant to Insulin Resistance \u2029and Lung Cancer].","authors":"Xiaoyu Chen, Peng Chen","doi":"10.3779/j.issn.1009-3419.2024.106.27","DOIUrl":"10.3779/j.issn.1009-3419.2024.106.27","url":null,"abstract":"<p><p>At present, the incidence and mortality rates of lung cancer rank top among malignant tumors. The early diagnosis, treatment and drug resistance of lung cancer still remain as problems in the management of lung cancer. Researchers are dedicated to identifying reliable biomarkers as predictive indicators or effective therapeutic targets for lung cancer. Insulin resistance (IR), a disorder characterized by reduced biological activity of insulin, leads to increased insulin secretion. In recent years, more and more studies have revealed the association between IR and the occurrence and development of cancer, with the insulin/insulin-like growth factor signaling pathway possibly playing a crucial role. In this article, we will focus on the relationship between IR and lung cancer, explore the impact and mechanism of IR on the development, progression and drug resistance of lung cancer. It may guide the development of new predictive tools and therapeutic strategies, and provide new ideas for research dedicated to reducing the incidence and mortality of lung cancer.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"755-762"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application of Patient-reported Outcomes and Shared Decision-making \u2029in Thoracic Surgery].","authors":"Weihao Chen, Mengni Zhang, Cheng Shen","doi":"10.3779/j.issn.1009-3419.2024.106.26","DOIUrl":"10.3779/j.issn.1009-3419.2024.106.26","url":null,"abstract":"<p><p>Thoracic surgery encompasses the diagnosis and treatment of various chest diseases such as lung cancer, esophageal cancer, and mediastinal tumors. The treatment plans for these diseases are complex and often involve a combination of surgery, chemotherapy, and radiotherapy, each with different impacts on the patient's quality of life. Patient-reported outcomes (PRO) and shared decision-making (SDM) are becoming increasingly important in this field. PRO allows patients to directly report their health status and the effects of treatment, aiding doctors in adjusting treatment plans. SDM ensures that treatment plans align with the patient's personal values and preferences through information sharing and joint decision-making. The comprehensive application of PRO and SDM can enhance patient satisfaction and treatment outcomes, though it also faces challenges such as data collection and time management. Future research should focus on developing more efficient PRO tools and SDM processes to improve patient-centered healthcare quality.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"792-798"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629092/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research and Progress on the Association of Porphyromonas gingivalis with Lung Cancer].","authors":"Yuanyuan Yin, Jie Zhang, Qiang Guo, Cheng Shen","doi":"10.3779/j.issn.1009-3419.2024.101.28","DOIUrl":"10.3779/j.issn.1009-3419.2024.101.28","url":null,"abstract":"<p><p>Porphyromonas gingivalis is a key pathogenic microorganism that triggers periodontitis. It is closely associated with oral diseases such as chronic periodontitis and recently found to have a significant correlation with the occurrence, progression, and prognosis of cancer. As the leading malignant tumor in terms of both incidence and mortality worldwide, lung cancer has always been a focus and hotspot of research. The causes of lung cancer are complex and involve multiple factors, including smoking, occupational factors, air pollution, ionizing radiation, diet and nutrition, genetic factors, etc. Researchers have also begun to pay attention to the relationship between oral microbiota and overall health, especially the link with lung cancer. The article summarizes the latest advancements in research on Porphyromonas gingivalis in lung cancer, primarily encompassing etiology and pathogenic mechanisms, and explores its potential as a therapeutic target for lung cancer, aiming to provide new insights and directions for lung cancer prevention and treatment strategies.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"799-804"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Real-world Study of the Safety and Efficacy of Pembrolizumab in the Treatment \u2029of Advanced Non-small Cell Lung Cancer].","authors":"Ning Wan, Bing Wang, Ya Guo, Zijian He, Chen Yang, Ning Yang, Liqing Lu, Hongyi Liang, Weibin Xiao, Dandan Yang, Zhuojia Chen, Wenfeng Fang, Weiting Liang","doi":"10.3779/j.issn.1009-3419.2024.106.29","DOIUrl":"10.3779/j.issn.1009-3419.2024.106.29","url":null,"abstract":"<p><strong>Background: </strong>Pembrolizumab (PEM) has been shown to be effective in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC), but clinical trials were based on cohorts of patients selected on specific criteria, and whether the findings are consistent with real-world patients is debatable. The aim of this study is to evaluate the efficacy and safety of PEM in the treatment of advanced NSCLC based on real-world data.</p><p><strong>Methods: </strong>A retrospective collection of real-world data from patients with advanced NSCLC receiving PEM was conducted. Propensity score matching was used to eliminate inter-group differences and assess the efficacy and safety of PEM compared to chemotherapy.</p><p><strong>Results: </strong>Among 450 matched patients, the incidence rates of any-grade adverse events were 79.87% in the PEM group and 86.71% in the chemotherapy group, while the incidence rates of grade ≥3 adverse events were 4.03% and 7.31%, respectively. The objective response rates were 48.63% for PEM and 36.00% for chemotherapy (P=0.011). The median progression-free survival was 15.5 months for PEM and 8.8 months for chemotherapy (P<0.001), and the median overall survival was not reached for PEM and 26.2 months for chemotherapy (P<0.001).</p><p><strong>Conclusions: </strong>PEM treatment for advanced NSCLC demonstrates favorable survival outcomes and acceptable safety in real-world clinical practice.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"745-754"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress and Perspectives of Antibody-drug Conjugates Targeting\u2029Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer].","authors":"Jingyan Xu, Jiaqi Liu, Shiqi Mei, Qing Zhou","doi":"10.3779/j.issn.1009-3419.2024.101.25","DOIUrl":"10.3779/j.issn.1009-3419.2024.101.25","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) remains a significant global health burden, and there is an urgent need for new treatment options. Trophoblast cell surface antigen-2 (TROP-2), a target closely associated with NSCLC prognosis, has become a research hotspot in recent years. Notably, TROP-2-targeted antibody-drug conjugates (ADCs) have made groundbreaking advances in NSCLC therapy. Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC, regardless of the presence of actionable genomic alterations. These agents have shown promising potential in both frontline and subsequent treatment settings. In terms of safety, while adverse effects affecting the hematologic, respiratory, and gastrointestinal systems are generally manageable, close clinical monitoring and timely management are still required. In conclusion, TROP-2 ADCs hold great promise in the treatment of NSCLC.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 10","pages":"763-776"},"PeriodicalIF":0.0,"publicationDate":"2024-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142781528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on SMARCA4 Mutation Non-small Cell Lung Cancer].","authors":"Lishan Peng, Wenzhao Zhong","doi":"10.3779/j.issn.1009-3419.2024.102.32","DOIUrl":"10.3779/j.issn.1009-3419.2024.102.32","url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is one of the most prevalent and deadliest cancers worldwide. While the use of targeted therapies and immunotherapies in precision medicine has improved outcomes for some patients, a significant portion of individuals still fail to benefit, emphasizing the need to investigate the underlying mechanisms of resistance. Survival analyses have shown that NSCLC patients with SMARCA4 mutations often have poor prognoses. SMARCA4, the core ATPase subunit of the SWI/SNF chromatin remodeling complex, plays a critical role in regulating gene transcription by modifying chromatin accessibility. This influences essential cellular processes such as differentiation and cell cycle regulation, and SMARCA4 is widely regarded as a tumor suppressor. This review will explore the role of SMARCA4 mutations in tumor progression, its clinicopathological features in NSCLC, its impact on treatment outcomes, and potential therapeutic strategies.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 9","pages":"704-710"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[PKM1 Regulates the Expression of Autophagy and Neuroendocrine Markers \u2029in Small Cell Lung Cancer].","authors":"Chenchen Tang, Yulong Jin, Peiyan Zhao, Lin Tian, Hui Li, Changliang Yang, Rui Zhong, Jingjing Liu, Lixia Ma, Ying Cheng","doi":"10.3779/j.issn.1009-3419.2024.102.33","DOIUrl":"10.3779/j.issn.1009-3419.2024.102.33","url":null,"abstract":"<p><strong>Background: </strong>Small cell lung cancer (SCLC) is known as recalcitrant cancer with high malignancy and heterogeneity. Immunotherapy has changed the treatment pattern of extensive-disease SCLC (ED-SCLC), but the beneficiary population is limited. Therefore, exploring new therapeutic strategies is an urgent clinical problem to be solved for SCLC. SCLC is characterized by highly active glycolytic metabolism and pyruvate kinase M1 (PKM1) is one of the isozymes of PK, an important rate-limiting enzyme in glycolysis pathway. Previous studies have shown that PKM1 is related to autophagy and drug sensitivity, however, how PKM1 regulates drug sensitivity in SCLC and its mechanism remain unclear. The aim of this study was to investigate the biological functions of PKM1 in SCLC, including its effects on proliferation, migration, autophagy, drug sensitivity, and expression of neuroendocrine (NE)-related markers in SCLC.</p><p><strong>Methods: </strong>Western blot was used to detect the expression level of PKM1 in SCLC cells. PKM1 gene-overexpressed SCLC cell lines were constructed by stable lentivirus transfection. Proliferation of cells and drug sensitivity were detected by MTT, and migration ability of cells was determined by Transwell. The level of autophagy was detected by flow cytometry. Western blot was used to determine the expression levels of NE-related proteins.</p><p><strong>Results: </strong>PKM1 was differentially expressed among various SCLC cell lines, and was lower in H1092 cells (P<0.01). Compared with the control group, there was no significant difference in proliferation level of PKM1 overexpressing H1092 cell, but the migration ability was significantly increased (P<0.001), the drug sensitivity was reduced, and the level of autophagy was inhibited (P<0.001). Additionally, overexpression of PKM1 could upregulate the expression of non-neuroendocrine (non-NE)-related proteins (P<0.01) and decrease the expression of NE-related proteins (P<0.01).</p><p><strong>Conclusions: </strong>PKM1 was differentially expressed in SCLC cell lines, and high expression of PKM1 did not affect the proliferation, but affected the migration of SCLC cells. PKM1 might affect drug sensitivity by inhibiting autophagy and regulating the expression of NE markers. These results provide a theoretical basis for exploring the role of PKM1 in SCLC.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 9","pages":"645-653"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress of Comprehensive Follow-up Management Strategy on the Natural History of Simultaneous, Persistent Multiple Pulmonary Ground-glass Nodules].","authors":"Chengming Huang, Yongzhao Zhou, Yujin Fang, Yanyang Liu, Li Wang, Yu Zhuo, Daxing Zhu","doi":"10.3779/j.issn.1009-3419.2024.106.25","DOIUrl":"10.3779/j.issn.1009-3419.2024.106.25","url":null,"abstract":"<p><p>The development and change patterns as well as the disease course management of multiple ground-glass nodules (GGNs) in the lungs are currently hotspots and difficulties in clinical lung cancer research. Understanding the latest advancements in the natural history of multiple GGNs is crucial for grasping the disease variation patterns and formulating management strategies. Meanwhile, utilizing advanced methods such as intelligent follow-up management platforms makes the long-term standardized management of GGNs possible. Therefore, this article provides an overview of the latest research advancements on the natural history of multiple GGNs and new experience in GGNs management.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 9","pages":"691-696"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534573/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A Comparative Study of the Efficacy and Safety of Immune Monotherapy versus \u2029Immunotheray Combined with Chemotherapy in Elderly Patients Aged 75 Years \u2029and Above with Advanced Non-small Cell Lung Cancer].","authors":"Yunye Mao, An Wang, Shu Sheng, Yangyang Jia, Xiangwei Ge, Jinzhao Zhai, Jinliang Wang","doi":"10.3779/j.issn.1009-3419.2024.101.21","DOIUrl":"10.3779/j.issn.1009-3419.2024.101.21","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;The malignant tumor that has the highest global morbidity and death rate is lung cancer, which primarily affects the elderly. The therapy landscape for non-small cell lung cancer (NSCLC) has transformed with the introduction of immune checkpoint inhibitors (ICIs). The purpose of this study was to compare the safety and efficacy of immune monotherapy and immunotheray combined with chemotherapy in patients with advanced NSCLC aged 75 years and above.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study retrospectively analyzed 111 patients with advanced NSCLC who were at least 75 years old and received treatment at the First or Fifth Medical Centers of the People's Liberation Army General Hospital from January 2018 to October 2022. These patients underwent first-line or second-line treatment, with 70 receiving immunotherapy combined with chemotherapy and 41 receiving immunotherapy alone. Propensity score matching (PSM) was used to match the baseline characteristics of the patients, including age, Eastern Cooperative Oncology Group performance status (ECOG PS) score, and the number of treatment lines. The study endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety assessment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;The median OS for the immunotherapy combined with chemotherapy group was 27.87 months, and the median PFS was 11.50 months. The median OS for the immune monotherapy group was 34.93 months, and the median PFS was 17.00 months. There were no significant differences in OS (P=0.722) and PFS (P=0.474) between the two groups, but a significant difference was observed in ORR (P=0.025). After PSM matching, each group comprised 27 patients. The median OS for the immunotherapy combined with chemotherapy group was 17.70 months, the median PFS was 8.97 months. The median OS for the immune monotherapy group was 17.87 months, and the median PFS was 11.53 months. No significant differences were observed in OS (P=0.635), PFS (P=0.878) and ORR (P=0.097). In terms of safety, the overall incidence of adverse events (AEs) before matching was 62.86% in the immunotherapy combined with chemotherapy group, which was higher than 41.46% in the immune monotherapy group (P=0.029), while there was no difference in the incidence of AEs of grade 3 or above between the two groups (P=0.221). After matching, AEs occurred in 17 (62.96%) patients in the immunotherapy combined with chemotherapy group and 13 (48.15%) in the immune monotherapy group. There were no significant differences in the overall incidence of AEs (P=0.273) or the incidence of grade 3 or above (P=0.299) between the two groups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;Immunotherapy combined with chemotherapy does not significantly improve OS or PFS in patients with NSCLC aged 75 years and above when compared to immunotherapy alone, and this conclusion was further validated by the analysis after PSM. The safety assessment suggests that ","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"27 9","pages":"665-673"},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11534547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}